Hayley Virgil


Reduce Recurrence in Early-Stage NSCLC

May 05, 2021

Edward S. Kim, MD, highlights the impact of osimertinib in the treatment of patients with EGFR-mutant non–small cell lung cancer, next steps with the agent, and the importance of early genetic testing to provide personalized care.

HRD Testing Expands, But Still Lacks Standardization in Ovarian Cancer

April 09, 2021

Two tests for homologous recombination deficiency have been FDA approved for patients with ovarian cancer, including myChoice CDx and FoundationOne CDx, and they produce important information that can be used to guide treatment decisions.